dihydroartemisinin-piperaquine
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
combination drug |
| gptkbp:activeIngredient |
gptkb:dihydroartemisinin
gptkb:piperaquine |
| gptkbp:approvedBy |
gptkb:Australia
gptkb:China |
| gptkbp:ATCCode |
gptkb:P01BF05
|
| gptkbp:brand |
Duo-Cotecxin
Eurartesim |
| gptkbp:contraindication |
prolonged QT interval
|
| gptkbp:discoveredBy |
Chinese scientists
|
| https://www.w3.org/2000/01/rdf-schema#label |
dihydroartemisinin-piperaquine
|
| gptkbp:introducedIn |
2008
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits heme detoxification in Plasmodium
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
QT prolongation
gastrointestinal upset |
| gptkbp:usedFor |
malaria
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:WHOPrequalified |
yes
|
| gptkbp:bfsParent |
gptkb:artemisinin_combination_therapy
|
| gptkbp:bfsLayer |
6
|